Changes in Plasma Coagulation Markers with Prophylactic Treatment of Low Molecular Weight Heparin after Cesarean Section

ABSTRACT

Cesarean section has been identified as a major risk factor for thromboembolism, and additional risk factors place some women at a much higher risk during puerperium. Recently, low molecular weight heparins (LMWHs) have been used for thromboembolism prophylaxis after cesarean section. We investigated the effect of risk factors of thromboembolism on plasma coagulation markers when the LMWH dalteparin was used following cesarean section. Twenty-four women with risk factors other than cesarean section (high-risk group) and 13 without any other risk factors (low-risk group) received dalteparin starting immediately after cesarean section until the patients were mobilized. Sixteen women without any other risk factors served as controls (control group). Activated partial thromboplastin times, thrombin-antithrombin complex, α₂-plasmin inhibitor-plasmin complex, and activated factor X levels were not different between the high-risk and the low-risk groups. However, fibrinogen/fibrin degradation products D-dimer levels were higher in the high-risk group than in the low-risk and control groups on days 3 and 7 after cesarean section. These findings suggest that the D-dimer levels may be elevated by some risk factors and that postoperative D-dimer determinations may be useful in assessing the risk of thromboembolism during LMWH treatment after cesarean section.

Low molecular weight heparins - cesarean section - thromboembolism - coagulation markers - risk factors

REFERENCES

• 1 Department of Health, Welsh Office, Scottish Home and Health Department and Department of Health and Social Services Northern Ireland .Confidential Enquiries into Maternal Deaths in the United Kingdom 1994-1996. London; HMSO 1998
• 2 Berj C J, Atrash H K, Koonin L M, Tucker M. Pregnancy-related mortality in the United States 1987-90.  Obstet Gynecol. 1996;  88 161-167
• 3 Greer I A. Epidemiology risk factors and prophylaxis of venous thromboembolism in obstetrics and gynaecology.  Baillieres Clin Obstet Gynaecol. 1997;  11 403-430
• 4 Nelson-Piercy C. Obstetric thromboprophylaxis.  Br J Hosp Med. 1996;  55 404-408
• 5 Sturridge F, de Swiet M, Letsky E. The use of low molecular weight heparin for thromboprophylaxis in pregnancy.  Br J Obstet Gynaecol. 1994;  101 69-71
• 6 McColl M, Ramsay J E, Tait R C et al.. Risk factors for pregnancy associated venous thromboembolism.  Thromb Haemost. 1997;  78 1183-1188
• 7 Simpson E L, Lawrenson R A, Nightingale A L, Farmer R DT. Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database.  BJOG. 2001;  108 56-60
• 8 Lane D A, Macgregor I R, Michalski R, Kakkar V V. Anticoagulant activity of four unfractionated and four fractionated heparins.  Thromb Res. 1978;  12 257-271
• 9 Forestier F, Sole Y, Aiach M et al.. Absence of transplacental passage of fragmin (Kabi) during the second and third trimesters of pregnancy.  Thromb Haemost. 1992;  67 180-181
• 10 Omri A, Delaloye J F, Anderson H, Bachmann F. Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy.  Thromb Haemost. 1989;  61 55-56
• 11 Melissari E, Parker C J, Wilson N V et al.. Use of low molecular weight heparin in pregnancy.  Thromb Haemost. 1992;  68 652-656
• 12 Bertoli D, Borelli G. Peri- and postnatal teratology and reproductive studies of a low molecular weight heparin in rats.  Arzneimittelforschung. 1986;  36 1260-1263
• 13 Richter C, Sitzmann J, Lang P et al.. Excretion of low molecular weight heparin in human milk.  Br J Clin Pharmacol. 2001;  52 708-710
• 14 Royal College of Obstetricians and Gynaecology .Report on RCOG Working Party on Prophylaxis Against Thromboembolism in Gynaecology and Obstetrics. London; RCOG Press 1995
• 15 Lowe G DO, Greer I A, Cooke T G et al.. Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic risk factors THRIFT consensus group.  BMJ. 1992;  305 567-574
• 16 Hiremath V S, Gaffney G. Audit of thromboprophylaxis following caesarean section.  Ir Med J. 2000;  93 234-236
• 17 Banias B B, Nolan T E, Devoe L D, Krauss J S. Maternal coagulation inhibitors and the effects of cesarean delivery.  J Reprod Med. 1992;  37 741-744
• 18 Bellart J, Gilabert R, Fontcuberta J et al.. Levels of coagulation inhibitors and thrombin-antithrombin III complexes in normal pregnancy.  Med Sci Res. 1997;  25 699-702
• 19 Uszynski M. Generation of thrombin in blood plasma of non-pregnant and pregnant women studied through concentration of thrombin-antithrombin III complexes.  Eur J Obstet Gynecol Reprod Biol. 1997;  75 127-131
• 20 Hayashi M, Hamada Y, Ohkura T. Thrombin-antithrombin complex and alpha2-plasmin inhibitor-plasmin complex levels after cesarean section in normal pregnancies and pre-eclampsia.  Int J Gynaecol Obstet. 2003;  82 213-216
• 21 Hafner G, Schinzel H, Ehrenthal W et al.. Influence of blood sampling from venipunctures and catheter systems on serial determinations of prothrombin activation fragment 1+2 and thrombin-antithrombin III complex.  Ann Hematol. 1993;  67 121-125
• 22 Iversen L H. Pre-analytical variation on the measurements of sensitive markers of coagulation and fibrinolysis: the influence of venipuncture and mixing of blood.  Haemostasis. 1997;  27 119-124
• 23 Cofrancesco E, Cortellaro M, Corradi A et al.. Coagulation activation markers in the prediction of venous thrombosis after elective hip surgery.  Thromb Haemost. 1997;  77 267-269
• 24 Bongard O, Wicky J, Peter R et al.. D-Dimer plasma measurement in patients undergoing major hip surgery: use in the prediction and diagnosis of postoperative proximal vein thrombosis.  Thromb Res. 1994;  74 487-493
• 25 Hofmann M, Rest A, Hafner G et al.. D-Dimers, thrombin-antithrombin-III complexes (TAT), and prothrombin fragment 1.2 (PTF): parameters for monitoring therapy of low-molecular-weight heparin in coagulation disorders.  Anaesthesist. 1997;  46 689-696
• 26 Vukovich T, Proidl S, Teufelsbauer H et al.. Laboratory monitoring of thromboprophylaxis with low molecular weight and standard heparin.  Thromb Res. 1992;  66 735-743